161 related articles for article (PubMed ID: 25164143)
21. Thermal combination therapies for local drug delivery by magnetic resonance-guided high-intensity focused ultrasound.
Hijnen N; Kneepkens E; de Smet M; Langereis S; Heijman E; Grüll H
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4802-E4811. PubMed ID: 28566498
[TBL] [Abstract][Full Text] [Related]
22. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
23. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation.
Kleiter MM; Yu D; Mohammadian LA; Niehaus N; Spasojevic I; Sanders L; Viglianti BL; Yarmolenko PS; Hauck M; Petry NA; Wong TZ; Dewhirst MW; Thrall DE
Clin Cancer Res; 2006 Nov; 12(22):6800-7. PubMed ID: 17121901
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy.
Maples D; McLean K; Sahoo K; Newhardt R; Venkatesan P; Wood B; Ranjan A
Int J Hyperthermia; 2015; 31(6):674-85. PubMed ID: 26185910
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
26. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
27. The effect of injected dose on localized tumor accumulation and cardiac uptake of doxorubicin in a Vx2 rabbit tumor model using MR-HIFU mild hyperthermia and thermosensitive liposomes.
Cheng B; Bing C; Staruch RM; Shaikh S; Wodzak Staruch M; Szczepanski D; Williams NS; Laetsch TW; Chopra R
Int J Hyperthermia; 2020; 37(1):1052-1059. PubMed ID: 32892667
[TBL] [Abstract][Full Text] [Related]
28. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation.
Ahmed M; Goldberg SN
Int J Hyperthermia; 2004 Nov; 20(7):781-802. PubMed ID: 15675672
[TBL] [Abstract][Full Text] [Related]
29. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.
Zagar TM; Vujaskovic Z; Formenti S; Rugo H; Muggia F; O'Connor B; Myerson R; Stauffer P; Hsu IC; Diederich C; Straube W; Boss MK; Boico A; Craciunescu O; Maccarini P; Needham D; Borys N; Blackwell KL; Dewhirst MW
Int J Hyperthermia; 2014 Aug; 30(5):285-94. PubMed ID: 25144817
[TBL] [Abstract][Full Text] [Related]
30. Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer.
Lokerse WJM; Bolkestein M; Dalm SU; Eggermont AMM; de Jong M; Grüll H; Koning GA
J Control Release; 2017 Jul; 258():34-42. PubMed ID: 28479096
[TBL] [Abstract][Full Text] [Related]
31. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model.
Aoki H; Kakinuma K; Morita K; Kato M; Uzuka T; Igor G; Takahashi H; Tanaka R
Int J Hyperthermia; 2004 Sep; 20(6):595-605. PubMed ID: 15370816
[TBL] [Abstract][Full Text] [Related]
33. Real-time fluorescence imaging for visualization and drug uptake prediction during drug delivery by thermosensitive liposomes.
Motamarry A; Negussie AH; Rossmann C; Small J; Wolfe AM; Wood BJ; Haemmerich D
Int J Hyperthermia; 2019; 36(1):817-826. PubMed ID: 31451077
[No Abstract] [Full Text] [Related]
34. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
35. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
36. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
37. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
[TBL] [Abstract][Full Text] [Related]
38. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
[TBL] [Abstract][Full Text] [Related]
40. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
